申请人:Huang Danzhi
公开号:US20110077401A1
公开(公告)日:2011-03-31
The invention relates to compounds of formula 1, tautomers and salts thereof, wherein R
1
, R
2
, R
3
, R
4
, and R
5
have the meanings indicated in the specification. These compounds are receptor tyrosine kinase EphB4 inhibitors useful for the treatment of angiogenesis dependent cancers and intraocular neovascular syndromes. The invention further relates to a method termed ALTA (anchor-based library tailoring) of selecting compounds from a large compound library for screening as EphB4 inhibitors by computational procedures.
该发明涉及公式1的化合物,其互变异构体和盐,其中R1、R2、R3、R4和R5具有规范中指示的含义。这些化合物是受体酪氨酸激酶EphB4抑制剂,对于治疗依赖于血管生成的癌症和眼内新生血管综合征非常有用。该发明还涉及一种称为ALTA(基于锚定的库定制)的方法,通过计算程序从大型化合物库中选择化合物进行筛选,作为EphB4抑制剂。